Biocon Reports 9% Increase in Total Income as Biopharma Revenue Surges in Q1FY27

Biocon Reports 9% Increase in Total Income as Biopharma Revenue Surges in Q1FY27​

Bengaluru: Biocon Limited announced consolidated financial results for the fiscal first quarter of FY27, ending June 30, 2026. The company reported a total income of Rs 4,391 crore, marking a 9% year-on-year increase, alongside a Net Profit before exceptional items of Rs 145 crore.

The results reflect strong momentum in the Biopharma segment. Consolidated operating revenue rose 10% year-over-year (YoY) to Rs 4,336 crore. Consolidated EBITDA stood at Rs 902 crore, achieving a margin of 21%. The company also reported significant improvements in its balance sheet health, noting that interest costs decreased by 23% YoY from Rs 277 crore to Rs 213 crore.

Financial Highlights (Consolidated)​

The financial performance breakdown for Q1FY27 compared against the corresponding period in Q1FY26 is summarized below:

Segmental Performance and Market Expansion​

The robust performance was significantly driven by the Biopharma segment. Biopharma revenue grew 17% YoY to Rs 3,615 crore. This growth was supported by:

• Biosimilars: Revenue increased 16% YoY to Rs 2,855 crore.
• Generics: Revenue rose 21% YoY to Rs 760 crore.
• Services: Services revenue decreased 16% YoY to Rs 736 crore due to market challenges faced in the previous year.

Biocon successfully expanded its presence globally, leveraging new product launches and regulatory milestones. In North America, growth was boosted by the ramp-up of biosimilars such as Bosaya™ and Aukelso™ (biosimilar Denosumab), alongside commercialization of Yesafili™ (aflibercept-jbvf) in August. The company also secured a Health Canada Notice of Compliance (NOC) for Yesintek® (biosimilar Ustekinumab) autoinjector pen. Furthermore, Biocon commercialized Evfraxy® (biosimilar Denosumab) across several European markets and secured approval for Yesafili™ as Malaysia's first biosimilar Aflibercept.

Leadership Commentary and Strategic Focus​

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, stated that the company entered FY27 with a clear focus on converting strategic investments into long-term value creation. She noted that a favorable policy environment for biosimilars, coupled with expanded manufacturing capabilities in the U.S., reinforces confidence in North America's long-term opportunities.

Shreehas Tambe, CEO & Managing Director of Biocon Limited, commented that the company delivered a resilient performance in Q1FY27, highlighting the strength of its diversified portfolio and disciplined execution. He mentioned successfully launching Bosaya™ and Aukelso™, Yesafili™, and generic Liraglutide in the U.S., along with securing regulatory approval from the European Medicines Agency (EMA) for the new drug product fill-finish plant for insulins in Malaysia.

Siddharth Mittal, CEO & Managing Director of Syngene International Limited, stated his commitment to working closely with the Board and leadership team to translate priorities into tangible business outcomes for long-term growth. His immediate priorities include sharpening commercial execution, strengthening delivery across businesses, and building a more agile, cost-competitive organization while continuing investments in CDMO, AI, innovation, and differentiated scientific capabilities.

Business Developments​

In the services sector, Biocon signed an MoU with the BRIC-Translational Health Science and Technology Institute (THSTI) for collaborative research spanning early and late-phase clinical development and bioanalytical sciences. The company also continued to strengthen Syn.AI, its AI-enabled scientific platform intended to accelerate drug discovery services by screening larger libraries of molecules.

On an awards front, Kiran Mazumdar-Shaw was ranked No. 6 on Fortune India's 100 Most Powerful Women 2026 list and recognized for 'Lifetime Contribution to UK-India Relations' at the 10th edition of India Global Forum's UK-India Week. Biocon was recognized as a trailblazing brand by the 8th ET NOW's Iconic Brands of India.

BIOCON Stock Price Movement​

Today, Biocon Limited shares edged higher in the close, settling at ₹425.20 after gaining 0.76% on the day. The equity saw steady trading volume today, with 3.3 million shares recorded as having been traded.